Skip to main content

Day: February 5, 2025

Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Bagsværd, 5 February 2025 – Financial report for the period 1 January 2024 to 31 December 2024                                                                                                                                                                        Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion. Operating profit was positively impacted by gross-to-net sales adjustments in the US and negatively impacted by impairment losses. Sales in North America Operations increased by 30% in Danish kroner (30% at CER). Sales in International Operations increased by 17% in Danish kroner (19% at CER). Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 271.8 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 21% in Danish...

Continue reading

Nykredit today announces the Annual Reports for 2024 – Nykredit Realkredit A/S

 To Nasdaq Copenhagen A/S5 February 2025Nykredit today announces the Annual Reports for 2024 of: Nykredit A/S, CVR no 12 71 92 48 Nykredit Realkredit A/S, CVR no 12 71 92 80 Nykredit Bank A/S, CVR no 10 51 96 08 Totalkredit A/S, CVR no 21 83 22 78  Michael Rasmussen, Group Chief Executive, comments on the Annual Report 2024:For the fourth consecutive year, Nykredit delivers its best full-year performance to date. This is naturally highly satisfactory. Our robust financial results demonstrate that Nykredit is stronger than ever. Thanks to our mutual ownership and attractive value propositions, we continue to welcome new customers. As a result, we recorded business growth and expanded our market position across our core business in 2024. We want to be the customer-owned alternative to the largest listed banks. This is why we...

Continue reading

JCDecaux to double the number of roadside screens in London

   JCDecaux to double the number of roadside screens in London Paris, February 5th, 2025 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, has unveiled its vision to double the number of digital roadside 2m² screens in London. The investment will make Out-of-Home the big reach medium increasing the number of digital roadside screens to 2,000 with the installation of 1,000 new London Digital Network (LDN) screens into the city’s expanding neighbourhoods – including: Battersea, Canning Town, Elephant and Castle, King’s Cross, Wandsworth and Wembley. Around 670 of these innovative screens will appear on TfL’s bus stops across London. Locations across the capital will be selected to give advertisers the highest attention and impact. The new 86” screens are 30% larger than the market average, higher...

Continue reading

Nykredit today announces the Annual Reports for 2024 – Nykredit Bank A/S

 To Nasdaq Copenhagen A/S5 February 2025Nykredit today announces the Annual Reports for 2024 of: Nykredit A/S, CVR no 12 71 92 48 Nykredit Realkredit A/S, CVR no 12 71 92 80 Nykredit Bank A/S, CVR no 10 51 96 08 Totalkredit A/S, CVR no 21 83 22 78  Michael Rasmussen, Group Chief Executive, comments on the Annual Report 2024:For the fourth consecutive year, Nykredit delivers its best full-year performance to date. This is naturally highly satisfactory. Our robust financial results demonstrate that Nykredit is stronger than ever. Thanks to our mutual ownership and attractive value propositions, we continue to welcome new customers. As a result, we recorded business growth and expanded our market position across our core business in 2024. We want to be the customer-owned alternative to the largest listed banks. This is why we...

Continue reading

Alm. Brand A/S – Interim report Q4 2024

Highly satisfactory Q4 performanceThe insurance service result for Q4 2024 was a profit of DKK 440 million (Q4 2023: DKK 287 million), equivalent to a combined ratio of 84.5 (Q4 2023: 89.3), driven by favourable developments both in Personal Lines and Commercial Lines Insurance revenue grew by 6.2% to DKK 2,845 million (Q4 2023: DKK 2,680 million), driven by sustained strong premium growth of 7.2% in Personal Lines and premium growth of 5.1% in Commercial Lines The undiscounted underlying claims ratio fell by 1.9 percentage points to 63.8% (Q4 2023: 65.7%), driven by the effects of profitability-enhancing measures in Personal Lines The expense ratio fell to 18.0 (Q4 2023: 19.0), and the implementation of synergy initiatives generated a positive accounting effect of DKK 138 million in Q4 2024 (Q4 2023: DKK 75 million) Satisfactory...

Continue reading

Pandora Delivers 13% Organic Growth in 2024 – Targeting 7-8% Growth in 2025

FY 2024 HIGHLIGHTS2024 was another successful year for Pandora. Delivering on the Phoenix strategy, Pandora continued to elevate itself as a full jewellery brand, driving more consumers into the brand. Revenue and EBIT increased by 13% to reach DKK 31.7 billion and DKK 8.0 billion, respectively. Organic growth ended at 13% (guidance of “11-12%”), comprising of like-for-like (LFL) of 7% and network expansion of 5%. The gross margin continued to strengthen and ended at 79.8%, up 120bp Y/Y. The EBIT margin remained solid at 25.2% (guidance at “around 25%”). This helped drive 17% EPS growth to a new record-high of DKK 65. Strong progress on working capital drove cash conversion of 85%. Leverage ended at 1.1x NIBD/EBITDA. Proposed dividend of DKK 20 per share and a new share buyback programme of DKK 4.0 billion to be completed no later...

Continue reading

Pandora Announces a New DKK 4.0 Billion Share Buy-Back Programme

The Board of Directors has decided to launch a new share buy-back programme under which Pandora will buy back own shares for a maximum consideration of DKK 4.0 billion in the period from 6 February 2025 to 30 January 2026 at the latest, both days inclusive. Pandora has appointed Nordea as the sole lead manager on the first DKK 1.3 billion tranche of the buy-back programme, which will run from 6 February 2025 and finish no later than 6 June 2025. The share buy-back programme is implemented in accordance with the safe harbour rules in Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (market abuse regulation). The programme will be implemented under the following framework:The maximum total consideration for Pandora shares bought back in the period of the entire programme is DKK 4.0 billion; Under...

Continue reading

CN’s 2024 Annual Financial Statements and Annual Information Form available on Company Website

MONTREAL, Feb. 05, 2025 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) announced today that the Company’s 2024 Annual Financial Statements, Notes thereto and Management’s Discussion and Analysis, and its 2024 Annual Information Form and Form 40-F, have been filed with Canadian and U.S. securities regulators and are now available in the “Investors” section of its website, www.cn.ca/investors. Printed copies of CN’s 2024 Annual Financial Statements, Notes thereto and Management’s Discussion and Analysis will also be available to shareholders free of charge upon request. About CNCN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation...

Continue reading

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ®’s final pivotal Phase 3 data, published in The Lancet, which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated IXCHIQ® vaccine induces a rapid and strong immune response....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.